US 11,987,847 B2
Detecting colorectal neoplasm
David A. Ahlquist, Rochester, MN (US); William R. Taylor, Lake City, MN (US); Douglas W. Mahoney, Elgin, MN (US); Graham P. Lidgard, Madison, WI (US); and Hatim T. Allawi, Middleton, WI (US)
Assigned to MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, Rochester, MN (US); and EXACT SCIENCES CORPORATION, Madison, WI (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US); and Exact Sciences Corporation, Madison, WI (US)
Filed on Dec. 14, 2020, as Appl. No. 17/120,500.
Application 17/120,500 is a continuation of application No. 16/738,718, filed on Jan. 9, 2020, granted, now 10,883,144.
Application 16/738,718 is a continuation of application No. 15/301,227, granted, now 11,078,539, previously published as PCT/US2015/022749, filed on Mar. 26, 2015.
Claims priority of provisional application 61/977,954, filed on Apr. 10, 2014.
Claims priority of provisional application 61/972,942, filed on Mar. 31, 2014.
Prior Publication US 2021/0102263 A1, Apr. 8, 2021
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/112 (2013.01); C12Q 2600/154 (2013.01)] 5 Claims
 
1. A method comprising:
extracting genomic DNA from a biological sample of a human individual suspected of having or having colorectal cancer or a large colorectal adenoma;
treating the extracted genomic DNA with bisulfite;
amplifying the bisulfite-treated genomic DNA using primers specific for SFMBT2 and CHST2; and
measuring a methylation level for SFMBT2 and CHST2 using methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genomic sequencing PCR.